Recent Posts

Mesomark test

Among the many challenges of managing mesothelioma are the difficulties in diagnosing and then following the disease for progression or response to treatments administered. One of the potential tools to help in this regard is an assay of soluble mesothelin related peptides, now a commercially available test called Mesomark. Mesothelin is a glycoprotein (a protein with sugar molecules attached to it) that is expressed on normal mesothelial cells but also over-expressed in patients with malignant pleural mesothelioma (MPM) as well as potentially in patients with peritoneal mesothelioma or ovarian cancer. Soluble mesothelin-related peptides (SMRPs) are believed to be either peptide fragments of mesothelin (peptides being pieces of larger proteins) or variant versions of mesothelin that don’t remain bound to the cell surface. These SMRPs can then end up in serum or pleural fluid.

Continue Reading Email Tweet Share
2 0 1 3Jul17

Managing Mesothelioma Q&A: What to Expect From Surgery

In another video from the Managing Mesothelioma Q&A series, I discuss a common question I receive about what a patient can expect post-surgery from their lungs and their ability to breath independently. For treating mesothelioma, leading surgeries used are pleurectomy and extrapleural pneumonectomy, which removes the lining of the affected lung or the entire lung, respectively. While each patient tolerates a surgery differently, there are a few tests that doctors can perform to give a patient a clearer picture of what to expect.

Continue Reading Email Tweet Share
2 0 1 3Jun13

Managing Mesothelioma Q&A: Exercising with Mesothelioma

In another installment of the Managing Mesothelioma video podcasts, I cover the topic of exercising with mesothelioma. While there is no specific exercise or exercise routine that will help prevent or diminish mesothelioma, exercising is important for one's health with or without cancer.

Continue Reading Email Tweet Share

In my second video podcast, I explain the side effects that a mesothelioma patient can expect when administered chemotherapy treatments. Cisplatin and Alimta® are the two most commonly used chemotherapy drugs and often a combination of the two drugs is given. If you or a loved one is about to undergo chemotherapy, I hope this information is useful in helping you prepare for your upcoming treatments.

Continue Reading Email Tweet Share

In my first video podcast, I answer the common question from malignant pleural mesothelioma patients about both the possible benefits and harm that can result from taking non-prescribed vitamins and supplements during treatment. While many patients believe that taking more vitamins and supplements means better health, I'll explain that more is not always better when it comes to recommending alternative therapies for patients undergoing treatment.

Continue Reading Email Tweet Share
Dr. West Trimodality Therapy

Among the many challenges in treating malignant pleural mesothelioma (MPM) is the limitation we have in not really being able to do larger, randomized trials easily, particularly in the small subset of patients who are really strong candidates for more aggressive treatment options (like surgery, which is typically a big procedure even by the standards of lung surgery.) The most aggressive protocols involve a sequence of chemotherapy, surgery, and chest radiation. What these studies tend to show is that there are certainly some patients who do extremely well after the most aggressive “multimodality therapy” for MPM. But do they do well because of the aggressive therapy or because they qualified for it?

Continue Reading Email Tweet Share
The Chemo Question

This morning in our thoracic oncology tumor board discussion, we reviewed a case of a 72 year-old man who is now diagnosed with malignant pleural mesothelioma (MPM) that is too advanced to consider surgery, and who is rather debilitated from emphysema and other longstanding medical problems. The best studied treatment for MPM is the chemotherapy combination of cisplatin and Alimta (pemetrexed), which has a proven survival benefit compared with cisplatin alone1. But cisplatin is an older chemotherapy agent that is notoriously challenging for even many fit patients to tolerate. This raises the question of whether there might be an alternative approach for patients who are unlikely or unwilling to tolerate the anticipated side effects of a cisplatin/Alimta combination, which often include nausea/vomiting, possible kidney damage, hearing loss, peripheral neuropathy (numbness and tingling from nerve damage), and sometimes other issues not typically seen with carboplatin. The data from a large European registry2 provide reassurance that the generally better tolerated combination of carboplatin/Alimta can provide comparable benefit for patients who are not candidates for the standard cisplatin-based regimen.

Continue Reading Email Tweet Share
Stethoscope

Among the many challenges of managing malignant pleural mesothelioma (MPM) is reliably assessing the response of the disease to our treatment. We don’t want to discard a treatment that is effective, nor do we want to have patients continue on a treatment that isn’t helpful but is causing significant side effects. In oncology, we typically grade our work by comparing an imaging study like a computerized tomography (CT) scan of the chest done after 2-3 cycles of systemic therapy (usually covering a 6-9 week interval) to a baseline scan performed prior to the start of treatment. As you’d suspect, significant tumor shrinkage is good, while growth is bad, and stable disease is somewhere in between. Typically, we want to continue our treatment in the absence of significant progression or prohibitive side effects.

Continue Reading Email Tweet Share
Dr. West

Hi, folks.

My name is Dr. Jack West, and I’m a medical oncologist specializing in thoracic oncology at Swedish Cancer Institute in Seattle, WA. Over the next year, I’ll be covering a broad range of topics related to malignant pleural mesothelioma; one of the cancers I treat, as well as speak and write about for the cancer community. Though it’s a relatively uncommon cancer in the US and around the globe, my corner of the country actually has the highest per capita incidence of mesothelioma. This is primarily because of the many shipyards in our area where people are exposed to asbestos, and our center has emerged as one of the leading places in the country for management of mesothelioma.

Continue Reading Email Tweet Share

About Dr. West

  • “Best Doctors, Medical Oncology” in Seattle Magazine (2007)
  • Finalist at the GSK National Medical Oncology Fellows’ Forum (2002)
  • Southwest Oncology Group Young Investigator (2001)
  • Graduated from Harvard Medical School (1996)
  • Graduated from Princeton University (1990)

Read more about Dr. West »

Connect
With Dr. West

Google+ Twitter

Free Mesothelioma Information Packet

Receive a comprehensive mesothelioma packet free of charge within 24 hours...

Yes   No

Get Started

Featured Authors

Staff Writers

Topics

Archive

Resources

1-800-336-0086
Newest Clinical Trials, Breaking Treatment News, Top Mesothelioma Experts

Treatment Alert Program

Please fill in the form below to request FREE Mesothelioma Treatment Alert information. It will be sent to you within 24 hours.

YesNo